The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
R. Soldi, T. Ghosh Halder, A. Weston, T. Thode, K. Drenner, R. Lewis, M. R. Kaadige, S. Srivastava, S. Daniel Ampanattu, R. Rodriguez del Villar, J. D. Lang, H. Vankayalapati, B. Weissman, J. Trent, W. Hendricks, S. Sharma
This study shows that the LSD1 inhibitor SP-2577 enhances anti-tumor immunity and PD-L1 expression in SWI/SNF-mutated ovarian cancer models.
bioRxiv · Jan 10, 2020Cancer Biology